Paul L. Prather - Publications

University of Arkansas for Medical Sciences, United States 
Pharmacology, Neuroscience Biology

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced tolerance and asymmetrical cross-tolerance to effects of indole quinuclidinone analogue PNR-4-20, a G protein biased CB1R agonist in mice: comparisons with Δ9-THC and JWH-018. The Journal of Pharmacology and Experimental Therapeutics. PMID 30833484 DOI: 10.1124/jpet.118.252965  0.92
2019 Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic Analysis of Glucuronidation of Synthetic Cannabinoid 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-25. PMID 30739533 DOI: 10.1080/00498254.2019.1580403  0.92
2018 Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ-THC. Frontiers in Pharmacology. 9: 1084. PMID 30319418 DOI: 10.3389/fphar.2018.01084  0.92
2018 Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL. The tamoxifen derivative ridaifen-B is a high affinity selective CB receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicology and Applied Pharmacology. PMID 29906493 DOI: 10.1016/j.taap.2018.06.009  0.68
2018 Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications. PMID 29522717 DOI: 10.1016/j.bbrc.2018.03.028  0.72
2018 Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome? Neuroscience Letters. 673: 24-27. PMID 29490230 DOI: 10.1016/j.neulet.2018.02.054  0.52
2018 Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. Life Sciences. 192: 151-159. PMID 29191644 DOI: 10.1016/j.lfs.2017.11.042  0.52
2017 Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development. Pharmacological Research. PMID 28838808 DOI: 10.1016/j.phrs.2017.08.008  0.92
2017 Yadlapalli JSK, Dogra N, Walbaum AW, Wessinger WD, Prather PL, Crooks PA, Dobretsov M. Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats. Anesthesia and Analgesia. PMID 28489639 DOI: 10.1213/ANE.0000000000002006  0.52
2017 Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends in Pharmacological Sciences. PMID 28162792 DOI: 10.1016/  0.92
2016 Franks LN, Ford BM, Prather PL. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Frontiers in Pharmacology. 7: 503. PMID 28066250 DOI: 10.3389/fphar.2016.00503  0.68
2016 Ford BM, Franks LN, Radominska-Pandya A, Prather PL. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. Plos One. 11: e0167240. PMID 27936172 DOI: 10.1371/journal.pone.0167240  0.68
2016 Yadlapalli JS, Ford BM, Ketkar A, Wan A, Penthala NR, Eoff RL, Prather PL, Dobretsov M, Crooks PA. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Pharmacological Research. PMID 27637375 DOI: 10.1016/j.phrs.2016.09.012  0.68
2015 Anthony Jalin AM, Rajasekaran M, Prather PL, Kwon JS, Gajulapati V, Choi Y, Kim C, Pahk K, Ju C, Kim WK. Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. Plos One. 10: e0141600. PMID 26517721 DOI: 10.1371/journal.pone.0141600  0.92
2015 Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacological Research. 102: 22-32. PMID 26361728 DOI: 10.1016/j.phrs.2015.09.006  0.92
2014 Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. European Journal of Pharmacology. 737: 140-8. PMID 24858620 DOI: 10.1016/j.ejphar.2014.05.007  0.92
2014 Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacology, Biochemistry, and Behavior. 124: 40-7. PMID 24857780 DOI: 10.1016/j.pbb.2014.05.010  0.92
2014 Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sciences. 97: 45-54. PMID 24084047 DOI: 10.1016/j.lfs.2013.09.017  0.92
2014 Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews. 46: 72-85. PMID 24063277 DOI: 10.3109/03602532.2013.839700  1
2013 Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Science International. 233: 416-22. PMID 24314548 DOI: 10.1016/j.forsciint.2013.10.002  0.92
2013 Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochemical and Biophysical Research Communications. 441: 339-43. PMID 24148245 DOI: 10.1016/j.bbrc.2013.10.057  0.92
2013 Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapys Journal of Pharmacology and Experimental Therapeutics. 346: 350-361. PMID 23801678 DOI: 10.1124/jpet.113.206003  0.92
2013 Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. Journal of Medicinal Chemistry. 56: 4537-50. PMID 23631463 DOI: 10.1021/jm400268b  0.92
2013 Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and Applied Pharmacology. 269: 100-8. PMID 23537664 DOI: 10.1016/j.taap.2013.03.012  1
2013 Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorganic & Medicinal Chemistry Letters. 23: 2019-21. PMID 23466226 DOI: 10.1016/j.bmcl.2013.02.025  0.92
2013 Choi IY, Ju C, Anthony Jalin AMA, Lee DI, Prather PL, Kim WK. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury American Journal of Pathology. 182: 928-939. PMID 23414569 DOI: 10.1016/j.ajpath.2012.11.024  0.92
2013 Ju C, Hwang S, Cho GS, Kondaji G, Song S, Prather PL, Choi Y, Kim WK. Differential anti-ischemic efficacy and therapeutic time window of trans- and cis-hinokiresinols: stereo-specific antioxidant and anti-inflammatory activities. Neuropharmacology. 67: 465-75. PMID 23287539 DOI: 10.1016/j.neuropharm.2012.12.006  0.92
2012 Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms. Cell Biology International. 36: 1171-83. PMID 22938397 DOI: 10.1042/CBI20120134  0.92
2012 Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2174-84. PMID 22904561 DOI: 10.1124/dmd.112.047530  1
2012 Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies Neuropharmacology. 63: 905-915. PMID 22771770 DOI: 10.1016/j.neuropharm.2012.06.046  0.92
2012 Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anti-Cancer Agents in Medicinal Chemistry. 12: 1211-20. PMID 22583404  1
2012 Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Molecular Cancer Therapeutics. 11: 1421-31. PMID 22553354 DOI: 10.1158/1535-7163.MCT-12-0026  1
2012 Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chemical Research in Toxicology. 25: 825-7. PMID 22404317 DOI: 10.1021/tx3000472  0.92
2012 Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochemical Pharmacology. 83: 952-961. PMID 22266354 DOI: 10.1016/j.bcp.2012.01.004  0.92
2012 Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 139-56. PMID 21970716 DOI: 10.3109/00498254.2011.609570  0.92
2011 Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity Plos One. 6. PMID 21755008 DOI: 10.1371/journal.pone.0021917  0.92
2011 Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, ... Prather PL, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine Analytical Chemistry. 83: 4228-4236. PMID 21506519 DOI: 10.1021/ac2005636  0.92
2011 Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Molecular Interventions. 11: 36-51. PMID 21441120 DOI: 10.1124/mi.11.1.6  0.72
2009 Prather PL, Seely KA, Levi MS. Notice of retraction. The Journal of Pharmacology and Experimental Therapeutics. 331: 1147. PMID 19940110  0.92
2009 Seely KA, Levi MS, Prather PL. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. The Journal of Pharmacology and Experimental Therapeutics. 330: 31-9. PMID 19359525 DOI: 10.1124/jpet.109.151654  0.92
2009 Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1496-504. PMID 19339377 DOI: 10.1124/dmd.109.026898  0.92
2007 Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry. 101: 87-98. PMID 17241118 DOI: 10.1111/j.1471-4159.2006.04346.x  0.92
2005 Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 315: 828-38. PMID 16081674 DOI: 10.1124/jpet.105.089474  0.72
2005 Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. The Journal of Pharmacology and Experimental Therapeutics. 314: 868-75. PMID 15901805 DOI: 10.1124/jpet.105.085282  0.72
2005 Tiwari MM, Prather PL, Mayeux PR. Mechanism of bradykinin-induced Ca2+ mobilization in murine proximal tubule epithelial cells. The Journal of Pharmacology and Experimental Therapeutics. 313: 798-805. PMID 15665141 DOI: 10.1124/jpet.104.080408  0.6
2002 Martin NA, Ruckle MB, VanHoof SL, Prather PL. Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand. The Journal of Pharmacology and Experimental Therapeutics. 301: 661-71. PMID 11961071  0.6
Show low-probability matches.